Zusammenfassung
Seit den ersten Berichten über die relativ spezifische antipsychotische Wirksamkeit des Chlorpromazins (Delay u. Deniker 1952) und des Reserpins (Kline 1954), hat sich die experimentelle Pharmakologie sehr intensiv bemüht, den Mechanismus der antipsychotischen Wirkung beider Substanzen und der vielen von ihnen abgeleiteten Verbindungen aufzuklären. Dies hat im wesentlichen zwei Gründe: Zum einen ist eine genaue Kenntnis des Wirkungsmechanismus eines Pharmakons immer noch eine der wesentlichen Grundlagen einer rationalen Pharmakotherapie. Zum anderen war die Suche nach dem Wirkungsmechanismus der Antipsychotika immer von der Hoffnung getragen, über den Wirkungsmechanismus einen Schlüssel zum Verständnis der biologischen Ursachen der Schizophrenie in die Hand zu bekommen (Carlsson 1978).
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
Literatur
Ackenheil M, Albus M, Bondy B, Müller-Spahn F, Winch U, Naber D (1985) Biochemical and neuroendocrine studies in schizophrenia: attemps to characterize the illness biochemically. In: Beckmann H, Riederer P (eds) Pathochemical markers in major psychoses. Springer, Berlin Heidelberg New York Tokyo, pp 78–87
Angrist B, Kaminen DP van (1984) CNS stimulants as tools in the study of schizophrenia. TINS 7: 388–390
Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie, 4. Aufl. Springer, Berlin Heidelberg New York Tokyo
Birkmayer W, Riederer P (1980) Die Parkinson-Krankheit Biochemie, Klinik, Therapie. Springer, Wien New York
Bischoff S, Delini-Stula A, Maitre L (1985) Blockade der Dopamin-Rezeptoren im Hippokampus als Indikator antipsychotischer Wirksamkeit: Korrelationen zwischen neurochemischen und psychopharmakologischen Wirkungen von Neuroleptika. In: Pflug B, Foerster K, Straube E (Hrsg) Perspektiven der Schizophrenie-Forschung. Fischer, Stuttgart, S 87–103
Bürki HR (1986) Effects of fluperlapin on dopaminergic systems in rat brain. Psychopharmacology 89: 77–84
Carlsson A (1978) Does dopamine have a role in schizophrenia? Biol Psychiatry 13: 3–21
Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differently affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5: 2539–2544
Crow TJ (1982) Schizophrenia. In: Crow TJ (ed) Disorders of neurohumoral transmission. Academic Press, London, pp 287–340
Crow TJ, Taylor GR, Tyrell DAJ (1986) Two syndromes in schizophrenia and the viral hypothesis. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 1: Epidemiology, aetiology and clinical features. Elsevier, Amsterdam, pp 83–96
Davis JM (1965) Efficacy of tranquilizing and antidepressant drugs. Arch Gen Psychiatry 13: 552–572
De Graaf JS, Pinder RM (1986) Antipsychotics of the future. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 2: Management and research. Elsevier, Amsterdam, pp 47–66
Delay J, Deniker P (1952) Cas de psychoses traités par la cure prolongée et continué de 4568 RP. Ann Med Psychol 110: 364
Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatrie 19: 134–139
DeLisi LE (1986) The third biannual winter workshop on schizophrenia. Arch Gen Psychiatry 43: 706–711
Ellison GD, Eison MS (1983) Continuous amphetamine intoxication: an animal model of the acute psychotic episode. Psychol Med 13: 751–761
Giannini AJ, Loiselle RH, Price WA, Giannini MC (1985) Chlorpromazine vs. meperidine in the treatment of phencyclidine. J Clin Psychiatry 46: 52–54
Goodwin GM, Metz A (1985) Neuroleptics. In: Grahame-Smith DG (ed) Psychopharmacology 2, Part 1: Preclinical psychopharmacology. Elsevier, Amsterdam, pp 206–238
Greenberg BD, Segal DS, Jacobs BL (1985) Hallucinogens: Phencyclidine. In: Grahame-Smith DG (ed) Psychopharmacology 2, Part 1: Preclinical psychopharmacology. Elsevier, Amsterdam, pp 343–363
Gruzelier JH (1986) Theories of lateralised and interhemispheric dysfunction in syndromes of schizophrenia. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 2: Management and research. Elsevier, Amsterdam, pp 175–187
Härnryd C, Bjerkenstedt L, Björk K (1984 a) Clinical evaluation of sulpiride in schizophrenic patients — A double-blind comparison with chlorpromazine. Acta Psychiatr Scand 69 [Suppl 311]:7–30
Härnryd C, Bjerkenstedt L, Gullberg B (1984b) Time course for the effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand 69 [Suppl] 3111:75–92
Jenner P, Marsden CD (1983) Neuroleptics. In: Grahame-Smith DG (ed) Psychopharmacology 1, Part 1: Preclinical psychopharmacology. Elsevier, Amsterdam, pp 180–247
Kline NS (1954) Use of rauwolfia serpentina benth in neuropsychiatric conditions. Ann NY Acad Sci 59: 107–117
Lindström L, Besev G, Stening G, Widerlöv E (1985) An open study of remoxipride, a benzamide derivative, in schizophrenia. Psychopharmacology 86: 241–243
Lund-Laursen A, Gerlach J (1986) Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity. Acta Psychiatr Scand 73: 17–21
Magnusson O, Fowler CJ, Köhler C, Ogren SO (1986) Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25: 187–197
McCreadie RG, Morrison D, Eccleston D, Gall RG, Loudon J, Mitchell MJ (1985) An open multicentre study of the treatment of florid schizophrenia with remoxipride. Acta Psychiatr Scand 72: 139–143
Nordberg A, Nyberg P, Windblad B (1985) Topographic distribution of choline acetyltransferase activity and muscarinic and nicotinic receptors in Parkinson brains. Neurochem Pathol 3: 223–236
Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Ängeby K, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102: 459–474
Ortiz A, Gershon S (1986) The future of neuroleptic psychopharmacology. J Clin Psychiatry 47 [Suppl 5]: 3–11
Pearlson GD (1981) Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 148: 25–33
Reisine TD, Fields JZ, Yamamura HI, Bird ED, Spokes E, Schreiner PS, Enna SJ (1977) Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci 21: 335–344
Reynolds GP (1983) Increased concentrations and lateral asymmetry of amygdale dopamine in schizophrenia. Nature 305: 527–529
Riederer P, Reynolds GP (1985) Brain biochemistry in schizophrenia an assessment. In: Beckmann H, Riederer P (eds) Pathochemical markers in major psychoses. Springer, Berlin Heidelberg New York Tokyo, pp 35–43
Roth RH, Bacopoulos NG, Bustos G, Redmond DE (1980) Antipsychotic drugs: differential effects on dopamine neurons in basal ganglia and mesocortex following chronic administration in human and nonhuman primates. In: Cattabeni F, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics. Raven Press, New York, pp 513–520
Rüther E (1986) Wirkungsverlauf der neuroleptischen Therapie. Fischer, Stuttgart
Sedvall G, Farde L, Persson A, Wiesel FA (1986) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 43: 995–1005
Seeman P (1986) Dopamine/neuroleptic receptors in schizophrenia. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 2: Management and research. Elsevier, Amsterdam, pp 243–251
Snyder SH (1982) Neurotransmitters and CNS disease: Schizophrenia. Lancet 11: 970–974
Snyder SH, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31: 58–61
StoofJC, Kebabian JW (1984) Two dopamine receptors: Biochemistry, physiology, and pharmacology. Life Sci 35: 2281–2296
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Müller, W.E. (1987). Neurobiochemie der Neuroleptika. In: Pichot, P., Möller, HJ. (eds) Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen. Tropon-Symposium, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83188-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-83188-1_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-18197-2
Online ISBN: 978-3-642-83188-1
eBook Packages: Springer Book Archive